Author archives: bocsciences

Therapeutic Protein Expression System


Expression system refers to the system that synthesizes recombinant proteins through specific cells and transfected DNA vectors, which can translate the supplied DNA genetic information into the amino acid sequence specific to the target protein. After translation, these molecules are affected by post-translational modification (PTM). There are significant differences in the frequency and complexity of ...

Continue reading

Precision Fermentation for the Alternative Protein Industry


What is Precision Fermentation

 

Precision fermentation is a technology that utilizes microorganisms as cell factories to produce specific functional components. It allows microorganisms to be programmed to afford complex organic molecules, such as proteins, enzymes, fats, vitamins, natural pigments, etc. In biology, fermentations refer to specific metabolic pathways that extract energy from molecules, usually in ...

Continue reading

BOC Sciences: A Robust Isotope Labeling Service Vendor


New York, United States—May 10, 2022—BOC Sciences is a robust supplier of stable isotope-labeled compounds in the United States. While realizing isotopic labeling with different molecules could be tricky sometimes, the company provides professional stable isotope labeling services for worldwide partners to support them from preclinical to commercial stages.

 

Stable isotope labeling involves ...

Continue reading

Innovative Impurity Isolation and Identification Techniques at BOC Sciences to Address Pharmaceutical Impurity Issues


New York, United States—June 30, 2022—BOC Sciences announced impurity isolation and identification services using traditional and innovative impurity techniques.

 

“We’re happy to have achieved consensus with global pharmaceuticals to deal with the NDMA risk and other impurity concerns. We will continue to provide full support taking advantage of our rich experience and ...

Continue reading

BOC Sciences Demonstrates Comprehensive Strength with LYTAC Technology


New York, United States—June 29, 2022—BOC Sciences, a leading CRO in the pharmaceutical industry, demonstrates its comprehensive strength through innovative lysosome-targeting chimera (LYTAC) degradation technology solutions developed within the field of targeted protein degradation.

 

LYTAC is a new technology that can degrade extracellular proteins and membrane-related proteins through the endosomal/lysosomal pathway. The ...

Continue reading

Peptides Labeling with Stable Isotope


Peptides are organic compounds formed by the dehydration of amino acids and intermediate products of protein hydrolysis. Peptides have strong biological activity, which can regulate the functional activities of cells in living organisms, and play a variety of roles in medicine, cosmetics, food, and other fields. With the more and more extensive and in-depth applications ...

Continue reading

Antibody-drug Conjugates Manufacturing and Future Focus


Antibody-drug conjugates (ADCs) are formed by covalent biochemical conjugation of monoclonal antibodies (mAb) with payload drugs through small molecular linkers. They are regarded as an emerging class of drugs designed for high-specificity targeting and destruction of cancer cells, since the specificity of mAb to tumor cells allows small-molecule drugs to target tumor tissues, effectively reducing ...

Continue reading

PROTAC-based Methods as Traditional PROTAC Protein Degradation Technology Alternatives


In recent years, the transition from inhibition of aberrant protein function to specific degradation of desired proteins with Proteolysis Targeting Chimeras (PROTACs) has resulted in remarkable progress and is currently affecting a paradigm shift in drug discovery and therapy development. PROTAC approach has allowed quick expansion of the “druggable proteome” beyond proteins that bear distinct ...

Continue reading